



Pharsight Launches Next Generation of Phoenix® Software Platform to Support Model Based Drug Development.

New Versions of WinNonlin, NLME, Connect and the IVIVC Toolkit Greatly Enhance the Power of the Phoenix Platform.

ST. LOUIS, MO – April 5, 2011 – Pharsight, a market-leading provider of software and scientific consulting services to improve productivity and decision-making in PK/PD modeling and simulation, announced today that a very significant suite of new and updated Phoenix software was launched today.

Phoenix is the industry standard PK/PD modeling and simulation platform that is used by more than 4,000 researchers at over 2,000 institutions worldwide, including the FDA. Last year, Pharsight trained over 500 users on the Phoenix WinNonlin and NLME tools as many organizations adopted Phoenix under a unique free upgrade path for all current users.

“This release of Phoenix represents another important milestone in the execution of Pharsight’s vision for an integrated, but open, software platform to support the industry’s demand for easier to use and more robust tools for PK/PD modeling,” said Daniel Weiner, Ph.D., General Manager of Pharsight Software. “Pharsight added more new users last year than any in our 25 year history. The reaction to the Phoenix platform has been overwhelmingly positive and we believe that our users will greatly appreciate the investments we have made in the new versions we are launching today.”

All software tools in Phoenix benefit from a set of enhancements made to the underlying platform. The new release will support Windows 7, and offers a Job Management System that will allow users to remotely execute compute intensive jobs. It includes a great number of enhancements to workflows, plotting, tables, licensing and the overall user experience. In addition, each of the individual tools contains enhancements that are specific to each tool, such as improvements to the analytical engines for population PK/PD modeling.

“With this release of Phoenix, users are getting a more mature, but modern platform that offers a wide range of capabilities,” added Dan Weiner. “For example, Phoenix uniquely offers the ability to perform population PK/PD modeling within a validated environment; the ability to build graphical workflows that can access third party tools such as R, PsN, Xpose, SAS, S-Plus and NONMEM; and the ability to build IVIVC correlations to optimize bioequivalence trial design, to name but a few.”

About Phoenix

Phoenix is the industry leading, state of the art PK/PD modeling software platform that includes a range of tools that can be used individually or together. All tools can be accessed within a single graphical user interface for ease-of-use. The currently available products on the Phoenix platform include:

- Phoenix WinNonlin 6.2
- Phoenix NLME 1.1
- Phoenix Connect 1.2
- IVIVC Toolkit 2.0 for Phoenix WinNonlin
- Phoenix Validation Suites

http://www.pharsight.com/products/prod_home.php

About Pharsight

Pharsight, a Certara™ company, is a market-leading provider of software products and scientific consulting services to help pharmaceutical and biotechnology companies improve their drug development process, regulatory compliance and strategic decision-making. Established in 1995, the company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Headquartered in St. Louis, Missouri, with more than 1200 customers worldwide, Pharsight products and services are used by all of the world's top 50 pharmaceutical firms. More information about Pharsight is available at www.pharsight.com.

About Certara

Certara is dedicated to improving human health through a broad spectrum of products and services, from molecular discovery to clinical research. Formed in 2008, Certara unites Tripos (www.tripos.com) and Pharsight Corporation (www.pharsight.com). Tripos provides innovative scientific solutions enabling life science researchers to improve the efficiency of molecular discovery. Pharsight provides software and scientific services to improve productivity and decision-making in clinical drug development. Certara focuses on reducing the barriers between the phases of research to speed discoveries in chemistry and enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.

Registered Trademarks and Trademarks

Pharsight, Pharsight Knowledgebase Server, PKS, PKS Online, Phoenix, Phoenix WinNonlin, Phoenix Connect and WinNonlin are trademarks or registered trademarks of Tripos, L.P. All other brands and product names are trademarks or registered trademarks of their respective holders.

Pharsight Contact:

Diana O'Rourke, 314-951-3310

Director of Marketing

diana.orourke@certara.com